Ombitasvir/paritaprevir/ritonavir, sold under the brand names Technivie and Viekira Pak among others, is a medication used to treat hepatitis C. It is a fixed dose combination of ombitasvir, paritaprevir, and ritonavir. Specifically it is used together with dasabuvir or ribavirin for cases caused by hepatitis C virus genotype 1 or 4. Cure rates are around 95%. It is taken by mouth.
It is generally well tolerated. Common side effects include nausea, itchiness, rash, and trouble sleeping. Other side effects include allergic reactions and reactivation of hepatitis B among those previously infected. Use is not recommended in those with significant liver problems. While there is no evidence of harm with use during pregnancy, this use has not been well studied. Each of the medications works by a different mechanism. The ritonavir is present to decrease the breakdown of paritaprevir.
Ombitasvir/paritaprevir/ritonavir with dasabuvir was approved for medical use in the United States in 2014 and without dasabuvir in 2015. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The cost in the United Kingdom is 32,199.99 pounds for 12 weeks of treatment. The wholesale cost for 12 weeks in the United States is 76,653.00 USD while the combination with dasabuvir cost 83,319.00.
